---
title: "Ironwood Pharmaceuticals' LINZESS Secures FDA Approval For Functional Constipation Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287788765.md"
description: "Ironwood Pharmaceuticals, Inc. (IRWD) announced FDA approval for LINZESS (linaclotide) to treat functional constipation in pediatric patients aged 2 and older. This makes LINZESS the only FDA-approved prescription therapy for this condition. The approval is based on a Phase 3 clinical trial showing improved bowel movement frequency. IRWD shares are currently trading at $3.98, up 2.18% on Nasdaq."
datetime: "2026-05-27T14:43:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287788765.md)
  - [en](https://longbridge.com/en/news/287788765.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287788765.md)
generator: "portal-rs"
---

# Ironwood Pharmaceuticals' LINZESS Secures FDA Approval For Functional Constipation Treatment

Add  as your preferred news source on Google

 Add Now

Wednesday, Ironwood Pharmaceuticals, Inc. (IRWD) announced that the U.S. Food and Drug Administration has approved the use of LINZESS, also known as linaclotide, in pediatric patients 2 years of age and older with functional constipation.

With this approval, LINZESS remains the only FDA-approved prescription therapy for pediatric functional constipation, a chronic condition characterized by hard, infrequent bowel movements.

The approval is backed by data from a 12-week Phase 3 randomized, placebo-controlled clinical trial, which demonstrated improvement in spontaneous bowel movement frequency compared with placebo. 

Currently, IRWD is trading at $3.98, up 2.18 percent on the Nasdaq. 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [IRWD.US](https://longbridge.com/en/quote/IRWD.US.md)

## Related News & Research

- [Ironwood Pharma to join Wells Fargo Healthcare Conference fireside chat](https://longbridge.com/en/news/297952760.md)
- [BioMarin submits FDA sNDA to expand Voxzogo use to children with hypochondroplasia](https://longbridge.com/en/news/298463433.md)
- [BridgeBio posts PROPEL 3 Phase 3 infigratinib data in children with achondroplasia presentation](https://longbridge.com/en/news/298422109.md)
- [Every project must deliver real value: Nam Long chairman](https://longbridge.com/en/news/298109923.md)
- [Aflac commemorates National Childhood Cancer and Sickle Cell Disease Awareness Month | AFL Stock News](https://longbridge.com/en/news/298460776.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**